Knight Therapeutics Inc T.GUD

Management Information Circular ...

[MrMugsy]

Now available on Sedar - Management Information Circular

Interesting detail - shows last year's voting for each board memeber.

Also ...
shows Amal is at almost double her share ownership expectation.
shows that Samira is at 42% of share ownership expectation and Arvind is at 39%.
both have until June 2026 to achieve the full ownership expectation.

There are, financial, operational and pipeline objectives for the team to hit.

etc...

[stkstroker]

I wonder if it's to their advantage to keep the share price down while they are aquiring thier position?

[EbbFlow88]

It's an advantage for all of us but I don't think they are trying to keep it down. 

[MrMugsy]

Agreed - nature of the beast with ~70% of the shares in 270 hands. The base of owners hasn't really changed. ----------------------- Here's the kind of scenario I'd be expecting over the next 5 years ... - purchase a few small drug portfolios for ROW or just a bunch of individual ROW drugs. - Novartis to pay close attention to GUD/EXELON as they rate GUD's abilities with ROW

[Chianchin]

On the contrary GUD is proped and over paying for it by the share buy back.  GUD has been a dud for 8 long years. No one is keeping it down 

[EbbFlow88]

Very interesting thesis. That would be great!

[Chianchin]

Indeed good ideas so to keep losing money for years to come

[MrMugsy]

From tiny seeds, might oaks will grow - think that's a fair comment from Goodman. - Foundation built and in final steps of being refined - Lots of cash - Taps on full for cash flow - large shelf prospectus on the ready This is an exciting lesson on how to build a sustainable pharma business from scratch.